196 related articles for article (PubMed ID: 31914238)
1. Abuses of FDA Regulatory Procedures - The Case of Suboxone.
Haffajee RL; Frank RG
N Engl J Med; 2020 Feb; 382(6):496-498. PubMed ID: 31914238
[No Abstract] [Full Text] [Related]
2. Factors Affecting Buprenorphine Utilization and Spending in Medicaid, 2002-2018.
Barenie RE; Sinha MS; Kesselheim AS
Value Health; 2021 Feb; 24(2):182-187. PubMed ID: 33518024
[TBL] [Abstract][Full Text] [Related]
3. Generic Drug Policy and Suboxone to Treat Opioid Use Disorder.
Haffajee RL; Frank RG
J Law Med Ethics; 2019 Dec; 47(4_suppl):43-53. PubMed ID: 31955697
[TBL] [Abstract][Full Text] [Related]
4. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
Yang YT; Chen B; Bennett CL
J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
[No Abstract] [Full Text] [Related]
5. Reforming the Orphan Drug Act for the 21st Century.
Sarpatwari A; Kesselheim AS
N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
[No Abstract] [Full Text] [Related]
6. Understanding the Rewards of Successful Drug Development - Thinking Inside the Box.
Khullar D; Ohn JA; Trusheim M; Bach PB
N Engl J Med; 2020 Jan; 382(5):473-480. PubMed ID: 31995697
[No Abstract] [Full Text] [Related]
7. The Orphan Drug Act Revisited.
Thomas S; Caplan A
JAMA; 2019 Mar; 321(9):833-834. PubMed ID: 30768155
[No Abstract] [Full Text] [Related]
8. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
Feldman R; Wang C
N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
[No Abstract] [Full Text] [Related]
9. Congress, the FDA, and the fair development of new medications for children.
McKinney RE
Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
[No Abstract] [Full Text] [Related]
10. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
11. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
12. Orphan products: an emerging trend in drug approvals.
Coté T; Kelkar A; Xu K; Braun MM; Phillips MI
Nat Rev Drug Discov; 2010 Jan; 9(1):84. PubMed ID: 20043031
[No Abstract] [Full Text] [Related]
13. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
14. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
15. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
16. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
17. New products highlight ambiguity of orphan drug law.
Reid B
Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896
[No Abstract] [Full Text] [Related]
18. FDA launches priority vouchers for neglected-disease drugs.
Waltz E
Nat Biotechnol; 2008 Dec; 26(12):1315-6. PubMed ID: 19060849
[No Abstract] [Full Text] [Related]
19. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
Clissold DB
Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
[No Abstract] [Full Text] [Related]
20. Pharmaceuticals and Medical Devices: FDA Oversight.
White RS;
Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-74. PubMed ID: 28252887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
